<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380091</url>
  </required_header>
  <id_info>
    <org_study_id>17-22550</org_study_id>
    <nct_id>NCT03380091</nct_id>
  </id_info>
  <brief_title>Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial</brief_title>
  <acronym>MINDD</acronym>
  <official_title>Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial: The MINDD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label randomized clinical trial assessing the efficacy of Metformin versus Vitamin D in
      improving symptoms of depressed mood in polycystic ovary syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, randomized, pilot clinical trial. Women with polycystic
      ovary syndrome and depressed mood, who are insulin resistant and vitamin D insufficient are
      eligible. Subjects are randomly assigned to one of two interventions: Vitamin D versus
      metformin. Subjects are followed with questionnaires and a final wrap-up clinic visit with a
      physician. The study duration is 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment challenges
  </why_stopped>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>12-week study duration</time_frame>
    <description>Symptoms of depression will be assessed by validated questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>12-week study duration</time_frame>
    <description>Lab testing will assess glucose and insulin homeostasis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>PCOS</condition>
  <condition>Depression</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1000 mg PO bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 5,000 IU PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral medication daily</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Oral medication daily</description>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Polycystic Ovary Syndrome diagnosis (Rotterdam Criteria)

          -  Vitamin D insufficiency (serum Vitamin D &lt;30 ng/mL)

          -  Insulin resistance

          -  Mild or greater severity of depression by Beck Depression Inventory-II

        Exclusion Criteria:

          -  Current metformin use

          -  Vitamin D supplementation of &gt; 50,000 IU following confirmation of Vitamin D
             insufficiency

          -  Insulin-dependent diabetes mellitus

          -  Pregnancy or breastfeeding

          -  Untreated hypothyroidism

          -  Current active substance abuse

          -  Other major medical comorbidity: renal or hepatic dysfunction, severe pulmonary

          -  Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Huddleston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Center for Reproductive Health</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Depression</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Mood disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

